GLPG1790 was able to decrease the phosphorylation/activation levels of EPH-A2 and EPH-B receptors, which are highly expressed and abnormally activated in ERMS cells lines and tumour biopsies (Fig. 1 for EPH-A2 and [18] for EPH-B). Here, EPHA2 is linked to neoplasm.